Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are studying the effects of intensified lipid-lowering therapy that includes Evinacumab on coronary plaque burden in patients with Homozygous Familial Hypercholesterolemia HoFH, a rare genetic disorder causing very high LDL cholesterol and increased risk of early heart disease. This observational study compares patients receiving Evinacumab with those on conventional lipid-lowering treatments, aiming to understand its impact on coronary atherosclerosis using coronary computed tomography angiography CCTA. Participants are divided into two groups based on their routine care one group receives Evinacumab added to stable lipid-lowering therapy, and the other continues standard lipid-lowering therapy without Evinacumab. Both retrospective and prospective data from approximately 52 patients across European centers will be collected, with CCTA scans performed at baseline and 18-24 months later to measure changes in coronary plaque volumes and characteristics. During the study, researchers will analyze CCTA images using artificial intelligence software to assess changes in non-calcified and total plaque volume and high-risk plaque features. Patient-reported outcomes and other exploratory measures will also be evaluated. All data come from routine clinical care without additional procedures mandated by the study. The study will monitor plaque changes and LDL cholesterol levels over 18-24 months, helping to understand the real-world effects of Evinacumab in managing cardiovascular risk in HoFH.
Actively Recruiting
Researchers are comparing two regional anesthesia methods to manage pain after elective total hip arthroplasty THA performed via the anterior approach. This randomized controlled trial evaluates the use of a Pericapsular Nerve Group PENG block combined either with a Lateral Femoral Cutaneous Nerve LFCN block or with wound infiltration WI to find which method better controls postoperative pain. The study focuses on pain intensity at rest six hours after surgery and also looks at other factors like opioid use and mobility. Participants will be randomly assigned to one of two groups. One group receives a PENG block with an LFCN block under ultrasound guidance, using 20 ml and 10 ml of 0.5% ropivacaine respectively, following neuraxial anesthesia. The other group receives a PENG block with 20 ml of 0.5% ropivacaine and a wound infiltration of 10 ml 0.5% ropivacaine after surgery. Both procedures are standard clinical practices with minimal additional risk. During the study, participants will be assessed for pain at rest and during movement at 6, 24, and 48 hours after regional anesthesia. Researchers will also measure opioid consumption, time to first rescue pain medication, muscle strength, hip flexion, length of hospital stay, and any complications. Safety is closely monitored throughout. Participation involves regular evaluations up to 48 hours post-surgery and observation of hospital stay length, with study activities concluding by November 2026.
Actively Recruiting
Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.